107 related articles for article (PubMed ID: 29987818)
1. Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis.
Zafar MU; Santos-Gallego CG; Badimon L; Badimon JJ
Methods Mol Biol; 2018; 1816():161-171. PubMed ID: 29987818
[TBL] [Abstract][Full Text] [Related]
2. Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate.
Jahn K; Suchodolski K; Schäfer A; Sahlmann B; Küster U; Echtermeyer F; Calmer S; Theilmeier G; Johanning K
Anesth Analg; 2017 Apr; 124(4):1091-1098. PubMed ID: 28244953
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
[TBL] [Abstract][Full Text] [Related]
4. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques.
Suades R; Padró T; Vilahur G; Badimon L
Thromb Haemost; 2012 Dec; 108(6):1208-19. PubMed ID: 23138460
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study.
Balasubramaniam K; Viswanathan G; Dragone J; Grose-Hodge R; Martin P; Troy S; Preston P; Zaman AG
Thromb Haemost; 2014 Jul; 112(1):205-15. PubMed ID: 24553755
[TBL] [Abstract][Full Text] [Related]
6. Visual evaluation of blood coagulation during mural thrombogenesis under high shear blood flow.
Mizuno T; Sugimoto M; Matsui H; Hamada M; Shida Y; Yoshioka A
Thromb Res; 2008; 121(6):855-64. PubMed ID: 17900667
[TBL] [Abstract][Full Text] [Related]
7. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
8. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal assays of thrombosis.
Badimon L; Padro T; Vilahur G
Methods Mol Biol; 2012; 788():43-57. PubMed ID: 22130699
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects.
Vilahur G; Baldellou MI; Segalés E; Salas E; Badimon L
Cardiovasc Res; 2004 Mar; 61(4):806-16. PubMed ID: 14985078
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
[TBL] [Abstract][Full Text] [Related]
12. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
[TBL] [Abstract][Full Text] [Related]
13. [Platelets and arterial thrombosis].
Cazenave JP; Gachet C; Lanza F; Wiesel ML
Bull Acad Natl Med; 2003; 187(1):35-44; discussion 45-6. PubMed ID: 14556452
[TBL] [Abstract][Full Text] [Related]
14. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi.
Badimon L; Chesebro JH; Badimon JJ
Circulation; 1992 Dec; 86(6 Suppl):III74-85. PubMed ID: 1424053
[TBL] [Abstract][Full Text] [Related]
15. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
16. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
17. The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model.
Ji S; Jiang M; Yan B; Shen F; He Y; Wan A; Xia L; Ruan C; Zhao Y
J Hematol Oncol; 2017 May; 10(1):111. PubMed ID: 28526067
[TBL] [Abstract][Full Text] [Related]
18. Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Petzold T; Thienel M; Konrad I; Schubert I; Regenauer R; Hoppe B; Lorenz M; Eckart A; Chandraratne S; Lennerz C; Kolb C; Braun D; Jamasbi J; Brandl R; Braun S; Siess W; Schulz C; Massberg S
Sci Transl Med; 2016 Nov; 8(367):367ra168. PubMed ID: 27903864
[TBL] [Abstract][Full Text] [Related]
19. Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model.
Bossavy JP; Cadroy Y; Sakariassen K; Boneu B; Barret A
Ann Vasc Surg; 1999 Jul; 13(4):393-401. PubMed ID: 10398736
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
